Ranbaxy Laboratories, the country's biggest drugmaker by sales, said on Tuesday it would set up a research and development facility in North America.\n\n\n\n
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
The initiative will be implemented through the Ranbaxy Community Health Care Society, a non profit organisation established by Ranbaxy, Daiichi and Ranbaxy said in a joint statement.
The process is being undertaken in consultation and agreement with the competent authorities.
Ranbaxy Laboratories has signed an agreement with Geneva's Medicines for Malaria Venture for developing synthetic peroxide anti-malarial drug
Last year, Ranbaxy had to pay a fine of $500 million to the US authorities after it pleaded guilty to fraudulent activities and misrepresenting data to seek fast approvals.
According to a report, the executives are T G Chandrashekhar, vice-president, global quality and analytical research, and Abha Pant, executive director for regulatory affairs.
Pharma major Ranbaxy Laboratories Ltd on Friday said it has received tentative approval from the US Food and Drug Administration to manufacture and market 25 mg, 100 mg and 200 mg Topiramate tablets.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
Ranbaxy's shares rose by 0.65 per cent on Thursday to close at Rs 493.55 a share, below the offer price of Rs 737 a share. Two days ago, it had been reported that institutional investors Life Insurance Corporation and General Insurance Corporation, which between them hold 16.43 per cent in Ranbaxy, offered to sell their stake.
In a boost to India's biggest drugmaker Ranbaxy Laboratories Ltd, an Austrian panel has ruled in the company's favour in a patent litigation against Pfizer involving cholesterol lowering drug 'Lipitor' in that country.
Ranbaxy, one of the first Indian companies to set up a venture in China in 1993, is bullish in its operations.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
Ranbaxy Laboratories will file an appeal against a New Jersey district court order restraining Teva Pharmaceuticals and Ranbaxy Pharmaceuticals Inc from selling RPI's quinapril tablets (5, 10, 20, and 40 mg) on a challenge filed by Pfizer.
All medicines that have USFDA approvals continue to be produced in the Poanta Sahib facility. The USFDA has not given any approval for new drugs as they have some concerns. We are addressing them, Malvinder Singh said.
India's largest drug manufacturer, Ranbaxy Laboratories, had falsified data and test results of medicines manufactured at its Himachal Pradesh facility to obtain marketing approval in the United States, says the US Food and Drug Administration.
Ranbaxy Laboratories Ltd on Tuesday launched its approved generic formulation of Clarithromycin immediate release tablets in the US market.
Sanjeev Dani, senior vice-president and regional director, Asia and CIS, Ranbaxy, said, "We are pleased to partner with Sirtex. We shall work towards creating a productive relationship."
The company has entered into an 'in-licencing agreement' with Gilead Sciences Inc to produce and sell, under licence, three new HIV/AIDS drugs which are currently in late stages of clinical development, Ranbaxy Laboratories said.
United States' Food and Drug Administration has granted approval to Ranbaxy Laboratories Ltd to manufacture and market 40 mg capsules of Fluoxetine, a drug used in treatment of obsessive-compulsive disorders.\n\n
Pharma major, Ranbaxy Laboratories Ltd has entered into a joint venture agreement with South African Community Investment Holdings to market and sell its range of Anti-Retroviral products in African markets.
It has hired consultants to advise it on a strategic project and compliance issues in the US. It also needs to improve employee morale.
Ranbaxy Laboratories on Tuesday announced a business alliance with Orchid Chemicals and Pharmaceuticals across multiple geographies and therapies, for finished dosage formulations and bulk drugs. The new alliance will explore new products and markets without disturbing the existing alliances. The deal is independent of any commitment related to management control and is a pure arm's length, independent strategic biz alliance. Ranbaxy will benefit from Orchid's future products
Close on the heels of a US district court ruling against its patent challenge of Pfizer's Lipitor, Ranbaxy Laboratories Ltd on Friday said it had entered into an out of court settlement with Cephalon Inc
A US court has ruled against Ranbaxy in its case for non-infringement and invalidation of two patents of its competitor Pfizer
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Ranbaxy requested withdrawal of approval under a consent decree.
US drug regulator's fiat on Mohali factory, after strictures on the two other major Indian units, has numerous negative implications.
Ranbaxy's troubled plants in India could see a turnaround as Sun Pharma has experience in doing so.
Pharma major denies charges, to file response soon.
The United States Food and Drugs Administration has granted Ranbaxy Laboratories a tentative approval to market a generic form of Bristol-Myers' anti-depressant Serzone, US FDA's web site said.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
Ranbaxy Laboratories Ltd on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances